Biotech Values

[Mpower]

wish i could see that. I am interested to see how the FDA responded to the irreparable harm/sovereign immunity argument set forth by Sanofi.

A PI, if granted, would likely cause irreparable harm to Sandoz. Thus, granting of one is likely "a wash", and I suspect the judge would want to maintain the status-quo. (thats my guess as a non-practicing attorney). It helps that the judge already refused to issue a TRO at the scheduling conference.

I wonder what the FDA said in their surreply to Sanofi's sovereign immunity argument...